SENSEX    74044.12       191.18    |    NIFTY    22411.2       8.80 FAQ    |    Feedback
EQUITIES
DERIVATIVES
IPO
Gainers & Losers Value & Volume Toppers 52 Weeks High/Low Advances & Declines
New High-Low
Pre-Session Mid-Session End-Session Other Markets Market Beat Stock Alert
Hot Pursuit Foreign Markets Economy News Corporate News Corporate Results
Detailed Quotes Board of Directors Balance Sheet Profit & Loss Quarterly Results Historical Price
Financial Ratios Company Background Technical Chart
Announcements Book Closure Board Meetings Bonus Issues Rights Issues
De-Listed Shares Name Change Split of Face Value Market Turnover
FII Investments MF Investments ADR Prices World Indices
Forthcoming IPOs
Open IPOs
Closed IPOs
New Listing
Basis Of Allotment Draft Prospectus New Issue Monitor
Get Quotes
Gainers
Losers
Value Toppers Advances & Declines Ticker Spot
Ticker Futures Closing Price Technical Chart Commodity News MCX Currency Futures
Get Quotes NIFTY Futures Top Traded Value Top Quantity Most Active Contracts
FII Statistics Daily Settlement Price List of Underlyings Put Call Ratio Derivative Summary
All Index Futures Top Gainers Top Losers Most Active Put Most Active Call
Highest in OI Lowest in OI Increase in OI Decrease in OI
Stock Alert
Overall view of all the recent market developments which will help in your investment decisions
Bharti Airtel, Bajaj Finance, Tata Consumer in spotlight
19-May-20   08:14 Hrs IST

On a consolidated basis, Bharti Airtel reported net loss of Rs 5,237 crore in Q4 March 2020 as compared with net profit of Rs 107.20 crore in Q4 March 2019. Total income rose 5.2% to Rs 23,913.60 crore in Q4 March 2020 over Q4 March 2019.

Consolidated EBITDA rose 51.7% to Rs 10,326 crore in Q4 March 2020 over Q4 March 2019. Consolidated EBIT increased by 172.1% to Rs 3,246 crore. The consolidated net loss before exceptional items was Rs 471 crore in Q4 March 2020.

Bajaj Finance declares its Q4 result today, 19 May 2020.

Glaxosmithkline Pharmaceuticals' consolidated net profit fell 5.95% to Rs 138.07 crore on 2.5% fall in total income to Rs 802.89 crore in Q4 March 2020 over Q4 March 2019.

Delta Corp's consolidated net profit fell 48.8% to Rs 29.04 crore on 12.17% fall in total income to Rs 191.30 crore in Q4 March 2020 over Q4 March 2019.

Astrazeneca Pharma India's net profit fell 2.44% to Rs 9.58 crore on 1% rise in total income to Rs 198.28 crore in Q4 March 2020 over Q4 March 2019.

Tata Consumer Products (TCPL) announced yesterday that it will acquire PepsiCo's stake in NourishCo Beverages, a 50:50 JV between the two companies. This move is consistent with Tata Consumer's focus on widening its portfolio in the Food and Beverages space.

Powered by Capital Market - Live News
MARKETS
TODAY'S MARKET SECTOR
BSE NSE
Currencies
Currency EUR GBP INR USD
Europe (EUR) 1.00 0.86 88.96 1.07
United Kingdom (GBP) 1.16 1.00 103.28 1.24
India (INR) 0.01 0.01 1.00 0.01
United States (USD) 0.94 0.81 83.31 1.00
Market News << ALL News
  25-Apr-2024, (09:26 )  Kotak Bank tumbles a..
  25-Apr-2024, (09:30 )  Kotak Mahindra Bank ..
  25-Apr-2024, (09:30 )  Macrotech Developers..
  25-Apr-2024, (08:28 )  Rites inks MoU with ..
 Commodities << ALL Commodities
   Attention Investor: Prevent unauthorized transactions in your trading / Demat account : Update your mobile number / e mail ids with your stock broker / deposit." | "No need to issue cheques by investors while subscribing to IPO.Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account." | "KYC is one time exercise while dealing in securities markets- once KYC is done through a SEBI registered intermediary(broker, DP, Mutual Fund etc.) you need not undergo the same process again when you approach another intermediary."
   Disclaimer   |   BSE Disclosure  |  Privacy Policy   |   Investor Protection   |    Inactive Account   |  Vernacular Language: NSE | BSE   |   Feedback   |    PMLA Policy   |   Risk Management Policy   |   Insider Trading   |   Investor Grivenances   |   Investor Complaints   |   Investor Charter   |   Rules And Regulations   |   Broker Norms   |   Terms of Use    Policies & Procedures   |   Risk Disclosure   |   Do & Don’ts   |   Rights & Obligations
  
SEBI Registration No : INZ000267132   |   BSE Clearing No : 333   
   Copyright © 2011 All rights reserved by Jaysukhlal Jagjivan Stock Broking Pvt.Ltd Designed, Developed & Powered By CMOTS INFOTECH (ISO 9001:2015 certified)